

OLYMPUS



Consolidated Financial Results for the 2nd Quarter for Fiscal Year 2025

Olympus Corporation | Director, Representative Executive Officer, Executive Chairperson and ESG Officer, Yasuo Takeuchi | Executive Officer and CFO, Tatsuya Izumi | November 8, 2024

Disclaimer

- This material contains forward-looking statements that reflect management's current views, plans, and expectations based on information available at the time of preparation. These forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, future business decisions, and other internal and external factors that may cause the Company's actual results, performance, achievements, or financial position to be materially different from any future results expressed or implied by these forward-looking statements.
- Additionally, this information is subject to change without notice. Accordingly, other information should be used in addition to this material when making investment decisions.
- This material is not intended for promotional or medical advice use. Products or devices presented include future technology which may be pending regional regulatory approval and are not available for sale in all regions. It is provided to give examples of technology development by Olympus and no guarantees are made about the future sale of such products.
- Olympus Corporation assumes no responsibility for any damage resulting from the use of this material.

Regarding the Recent Change in Representative Executive Officer and CEO

2Q (6M) Consolidated Financial Results

Revenue

¥474.0 billion



ESD +10% / +3%

+10% / +3%



TSD +10% / +3%

Adjusted operating profit

¥85.1 billion

+ ¥18.6 billion

Adjusted Operating Margin

17.9%

+2.5 pt

■ % YoY including FX
■ % YoY after FX adjustment

- 1 Achieved +24% (+15% after FX adj.) growth YoY in North America, with double-digit growth in all three focus areas of GI, Urology, and Respiratory.
- 2 Adjusted operating margin reached approx.18% in 6M (20% in 2Q), driven by tight SG&A control, etc.
- 3 Remediation and quality transformation program “Elevate” is continuing to progress well.
- 4 Balancing strong core customer demand, particularly in the U.S, with ongoing uncertainty in the business environment in China, the forecast remains unchanged.
- 5 Clearance/approval for cloud-based AI endoscopy devices in the U.S. and Europe, along with approval of competitive reimbursement rates for iTind in the U.S. are expected to support future growth.

Key Accomplishments and Outlook for Elevate Program

Present

Elevate is continuing to progress well

Key Accomplishments



Completed over **95%** of our commitments to the FDA to date



Launched first phase of new **Global Complaint Handling process**



Successfully completed **third-party audits¹** at our Aizu, Hinode, and Hachioji facilities

¹ Audits conducted by external consultants, confirmation, verification and FDA mock audits by independent third- parties

Future Plans

■ FY2026

Ready to complete our commitments to the FDA



Move on to the next phase of Elevate

■ FY 2027 and beyond

Expenses related to Elevate will decrease but some will transfer to SG&A enhancing QARA organizational capabilities

Clearance/Approval for Cloud-based AI Endoscopy Devices, a Significant Milestone in the Effort to Launch an Intelligent Endoscopy Ecosystem

Received clearance in the U.S. for one and approval under EU MDR for three cloud-based AI endoscopy standalone software medical devices.

✓ Significant milestone in our efforts to enhance clinical outcomes and operational efficiency in endoscopy

✓ Accelerate the launch of the platform with these CAD solutions



CADDIE

Cloud-based CADE¹ for colorectal polyps


- Assists in detection of colorectal polyps includes a Cecum AI function as convenience feature that provides a check to the user that the CADDIE polyp detection function is on and in use.

✓ U.S. FDA clearance

Cloud-based CADE¹ and CADx² for colorectal polyps

- Assists in detecting and characterizing suspected colorectal polyps including the Cecum AI and Visible Mucosa AI functions as convenience features.

✓ EU MDR approval



CADU

Cloud-based CADE¹ for potential dysplasia analysis

- Intended to aid in analyzing dysplasia in patients with Barrett's Esophagus during endoscopy procedures

- Analyzes data in real-time

✓ EU MDR approval



SMARTIBD

Cloud-based device for ulcerative colitis analysis

- Designed to aid in analyzing ulcerative colitis during colonoscopy procedures

- Processes colonoscopy video frames and provides real-time insights to help characterize tissue

✓ EU MDR approval



¹ CADE: Computer Aided Detection ² CADx: Computer Aided Diagnosis

Note: For detailed information regarding instructions for use, indications, contraindications, warnings, and precautions, please consult the device manual.

Timeline for the Realization of an Intelligent Endoscopy Ecosystem

Present

Key accomplishments:


- ✓ Roadshows¹ and product demonstrations received strong customer feedback
- ✓ Established six co-creation centers in Europe
- ✓ Piloting cloud-AI endoscopy systems in Europe

¹ Between February 2024 and October 2024 in Spain and Germany, with interested prospects and co-creation partners. Roadshow will continue.

Future Plans

- **FY2026 Q1**
Commercialize AI solutions in the U.S. and selected countries in the EMEA region
- **During FY2026**
Commercialize additional elements of the Intelligent Endoscopy Ecosystem in selected countries in the EMEA region

Digital Products



Note: The content includes technologies which are still under development, is to be considered preliminary and conceptual only, and is intended only for the discussion of the potential future use of such new technologies. Any features, benefits, or claims suggested or implied in this presentation may or may not be included in future technology when released to the market. Specifications, design, and accessories are subject to change without any notice or obligation on the part of the manufacturer. Technology shown may not be available in all countries and is not presently available in United States or Canada.


2Q of Fiscal Year 2025 Consolidated Financial Results

- 1 Revenue: Driven by North America, which achieved double-digit growth in three focus areas, led by “EVIS X1” GI endoscopy system. With yen depreciation serving as a tailwind, revenue increased by 10%.
- 2 Operating profit and Adjusted operating profit: Increased due to a decrease in losses related to Veran Medical Technologies, which were recorded in previous fiscal year, tight control of SG&A, and a tailwind from FX. Adjusted operating margin reached approx.18% in 6M (20% in Q2).

		6 Months (Apr. to Sep.)				Forecasts (Apr. to Mar.)	
(Billions of yen)		FY2024	FY2025	YoY	After FX adjustment	FY2025 Forecasts *No change since the announcement on May 10.	% of progress
Continuing operations ¹	Revenue	431.6	1 474.0	+10%	+3%	1,009.0	47%
	Gross profit	285.2	323.0	+13%	+3%	691.0	47%
	(% of revenue)	(66.1%)	(68.1%)	(+2.0%)		(68.5%)	
	Selling, general and administrative expenses	218.5	237.9	+9%	+3%	494.0	48%
	(% of revenue)	(50.6%)	(50.2%)	(-0.4%)		(49.0%)	
	Other income and expenses	-63.0	-14.5	-	-	-21.0	-
	Operating profit	3.8	2 70.5	+1,772%	+1,368%	176.0	40%
(% of revenue)	(0.9%)	(14.9%)	(+14.0%)		(17.4%)		
	Adjusted operating profit	66.5	85.1	+28%	+4%	197.5	43%
	(% of revenue)	(15.4%)	(17.9%)	(+2.5%)		(19.6%)	
	Profit before tax	-2.1	68.8	-	-	170.0	40%
	(% of revenue)	(-)	(14.5%)	(-)		(16.8%)	
Discontinued operation	Profit (loss)	216.7	49.0	-77%	-	121.0	40%
	Profit (loss) attributable to owners of parent	216.3	49.0	-77%	-	121.0	40%

¹ The figures from “Revenue” to “Profit from continuing operations” represent continuing operations.

2Q of Fiscal Year 2025 Endoscopic Solutions Division (ESD)



(Billions of yen)	FY2024 6M	FY2025 6M	FY2025 Forecasts	% of progress
Revenue	270.9	298.7	645.0	46%
Operating profit	50.9	62.6	162.0	39%
Other income and expenses	-7.8	-8.9	-12.5	-
Adjusted operating profit	58.7	71.5	174.5	41%
Operating margin (After FX adjustment)	18.8%	20.9% (18.2%)	25.1%	-
Adjusted operating margin (After FX adjustment)	21.7%	23.9% (21.2%)	27.1%	-

¹ Approx.


Growth Rate FY2025 6M vs
FY2024 6M

Incl. FX

After FX
adjustment

GI Endoscopy	9%	<ul style="list-style-type: none"> Growth of 44% in North America, where sales of EVIS X1 GI endoscopy system were strong. On the other hand, sales declined in China due to impact of anti-corruption campaign and other factors. EVIS X1 series accounts for approx. 25% of total GI Endoscopy sales. 	2%
Surgical Endoscopy	6%	<ul style="list-style-type: none"> Sales decreased in China, while increased in Europe. Growth driven by solid performance of VISERA ELITE III surgical endoscopy system etc., coupled with FX tailwind. 	0%
Medical Service	14%	<ul style="list-style-type: none"> Steady growth in all regions, especially in Europe and North America, due to stable revenue streams based on service contracts including maintenance services and an increase in new accounts. 	6%
Total	10%		3%

2Q of Fiscal Year 2025 Therapeutic Solutions Division (TSD)



(Billions of yen)	FY2024 6M	FY2025 6M	FY2025 Forecasts	% of progress
Revenue	159.7	175.0	363.0	48%
Operating profit	-28.5	26.8	54.5	49%
Other income and expenses	-54.7	-5.8	-7.5	-
Adjusted operating profit	26.1	32.7	62.0	53%
Operating margin (After FX adjustment)	-	15.3% (13.8%)	15.0%	-
Adjusted operating margin (After FX adjustment)	16.4%	18.7% (17.2%)	17.1%	-

¹ Approx.

Growth Rate FY2025 6M vs FY2024 6M

	Incl. FX		After FX adjustment
GI EndoTherapy	10%	▪ Growth primarily in North America and Europe. Sales increased in HPB ² (e.g. ERCP) products etc.	4%
Urology	14%	▪ Momentum primarily in North America and Europe. Sales increased in SOLTIVE SuperPulsed Laser System for urinary tract stone management and resection electrodes for benign prostatic hyperplasia (BPH) treatments.	6%
Respiratory	14%	▪ Growth primarily in North America and Europe. Notable momentum in therapeutic devices and EBUS scopes mainly used for endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA).	6%
Other therapeutic areas³	-1%	▪ Sales decreased in Japan etc. due mainly to discontinuation of handling other companies' products.	-7%
Total³	10%		3%

² HPB = hepato-pancreato-biliary ³ Considering the impact of the discontinuation of handling other companies' products, Other therapeutic areas grew by 6% YoY and 0% after FX adjustment. TSD grew by 11% YoY and 4% after FX adjustment.

Consolidated Statement of Financial Position

1 Assets decreased due to a decrease of cash and cash equivalents and FX impact (¥39.6 billion)

2 Bonds/loans payable decreased due to repayment of debts (Balance as of end of Sep.:¥245.5 billion)

(Billions of yen)	End of Mar. 2024	End of Sep. 2024	Change		End of Mar. 2024	End of Sep. 2024	Change
Current assets	800.3	657.1	-143.3	Current liabilities	431.7	419.6	-12.1
Cash and cash equivalents	340.9	245.9	-95.1	Bonds/loans payable	70.0	114.9	2 +44.9
Inventories	190.0	187.8	-2.2	Other current liabilities	299.9	250.9	-48.9
Non-current assets	733.9	709.6	-24.3	Non current liabilities	345.3	244.0	-101.4
Property, plant and equipment	260.0	249.5	-10.5	Bonds/loans payable	229.6	130.5	2 -99.1
Intangible assets	92.0	89.5	-2.5	Equity	757.2	703.1	-54.1
Goodwill	180.3	171.2	-9.1	(Equity ratio)	49.4%	51.4%	+2.0pt
Total assets	1,534.2	1,366.6	1 -167.6	Total liabilities and equity	1,534.2	1,366.6	-167.6

Consolidated Cash Flows

- 1 FCF: Although FCF decreased significantly YoY due to transfer of Evident in previous fiscal year, Adjusted FCF¹ was ¥39.3 billion
- 2 Financing CF: Minus ¥156.7 billion due mainly to share buyback, repayment of debts, and dividend payouts

6M (Apr. to Sep.)

(Billions of yen)		FY2024	FY2025	Change
Continuing operations	Profit before tax	-2.1	68.8	+70.9
	CF from operating activities (Operating CF)	-11.8	93.7	+105.5
	CF from investing activities (Investing CF)	412.7	-30.0	-442.7
	Free cash flow (FCF)	400.9	63.7	-337.2
	Adjusted Free cash flow (Adjusted FCF)	17.7	39.3	+21.6
	CF from financing activities (Financing CF)	-125.4	-156.7	-31.3
	Cash and cash equivalents at end of period	488.2	245.9	-242.3

Major adjusted items for FY2024 6M (Apr. to Sep.)

Operating CF: Corporate tax payment on gain on transfer of Evident	-¥56.7 billion
Investing CF: Receipt of consideration for transfer of Evident, etc.	+¥387.9 billion
Investing CF: Collection of loan from Evident, etc.	+¥52.0 billion

Major adjusted items for FY2025 6M (Apr. to Sep.)

Operating CF: Refund of corporation tax related to transfer of Evident	+¥29.0 billion
Operating CF: Outflow of reversal of provision for "Career support for external opportunity" program	-¥1.8 billion
Operating CF: Expenditures related to withdrawal from Veran Medical Technologies, Inc.	-¥1.2 billion
Investing CF: Purchase of investment securities	-¥8.5 billion
Investing CF: Payment of contingent consideration (Odin Medical, Arc Medical Design, etc.)	-¥3.0 billion
Investing CF: Income from transfer of Orthopedic Business	+¥5.2 billion
Investing CF: Refund associated with rescission of acquisition	+¥4.7 billion

¹ "Cash inflows and outflows of other income and expenses", "M&A-related expenditure", and "Business restructuring-related expenditure" are adjusted.


OLYMPUS

A thick, yellow, brushstroke-style underline that tapers at both ends, positioned directly beneath the word "OLYMPUS".

Appendix

Changes in Reporting Structure

Due to transfer of Orthopedic Business, which was included in Other, it is disclosed as a discontinued operation¹ from Fiscal Year 2025. Reportable segments² are now two: ESD and TSD (based on IFRS).




¹ In the six months ended September 30, 2024, Olympus Corporation entered into a put option agreement with PTCJ-6O Holdings Inc. and PTCJ-6F Holdings Inc. (special purpose companies established by Polaris Capital Group Co., Ltd., collectively, the “Polaris Capital Group”), to transfer Olympus Terumo Biomaterials Corporation and FH Ortho SAS, Olympus’s Orthopedic Business. Due to this, profit (loss) from the Orthopedic Business has been classified as profit (loss) from discontinued operation from the six months ended September 30, 2024, and it has been presented in the same manner for the six months ended September 30, 2023. Furthermore, the amounts presented for revenue, operating profit, adjusted operating profit, profit before tax and profit from continuing operations are the amounts from continuing operations from which the amounts from discontinued operation have been excluded, while the amounts presented for profit and profit attributable to owners of parent are aggregates of continuing operations and discontinued operation. In accordance with the put option agreement, the transfer of the Orthopedic Business was completed on July 12, 2024.

² IFRS 8.5-10 Segments that meet the requirements of “operating segments”, as determined by taking into account the aggregation criterion (IFRS 8.12) and the quantitative criterion (IFRS 8.13). Based on these standards, the Group previously had three reportable segments: “ESD,” “TSD,” and “Other”, but from the six months ended September 30, 2024, the Group has changed the reportable segments to two segments, “ESD” and “TSD,” and has presented the information in the same manner for the six months ended September 30, 2023.

2Q of Fiscal Year 2025 Factors that Affected Consolidated Operating Profit

6 Months (Apr. to Sep.)

(Billions of yen)



* Amounts in this slide are related to continuing operations only.

Key Product Catalysts: Endoscopic Solutions Division (As of Nov. 8, 2024)



✓ ESD Key priorities for FY2025

- Focus on further expanding sales of EVIS X1 gastrointestinal endoscopy system globally
- Collaborate with Canon Medical Systems to bring next-generation endoscopic ultrasound systems to the market. Expect to expand globally, starting with Europe, Japan, and Asia Pacific
- Maximize market potential in emerging countries
- Aim to introduce VISERA ELITE III surgical endoscopy system in the U.S. (at the end of FY2025) and China (FY2026) to improve market competitiveness
- Plan to roll out the Intelligent Endoscopy Ecosystem concept and some related products in Europe

Expected Growth Rates in FY2025

10%

YoY

6%

After FX adjustment

Growth drivers now	Just launched / Coming soon	Beyond
<p>GI Endoscopy</p> <ul style="list-style-type: none"> ▪ EVIS X1 ▪ EVIS EXERA III (US, EU) ▪ EVIS LUCERA ELITE (China) ▪ EU-ME3 (EU, Japan, AP) <p>Surgical Endoscopy</p> <ul style="list-style-type: none"> ▪ VISERA ELITE II 2D/3D/IR (US, China) ▪ VISERA 4K UHD (US, China) ▪ VISERA ELITE III (EU, Japan, AP) 	<p>GI Endoscopy</p> <ul style="list-style-type: none"> ▪ Aplio i800 EUS, diagnostic ultrasound system for EUS (US, EU, Japan, AP) ▪ EU-ME3 (US) <p>Surgical Endoscopy</p> <ul style="list-style-type: none"> ▪ VISERA ELITE III (US) <p>Focus Area</p> <ul style="list-style-type: none"> ▪ First releases of Intelligent Endoscopy Ecosystem¹(EU) 	<p>GI Endoscopy</p> <ul style="list-style-type: none"> ▪ Single-use duodenoscope ▪ EU-ME3 (China) <p>Surgical Endoscopy</p> <ul style="list-style-type: none"> ▪ VISERA ELITE III (China) <p>Focus Area</p> <ul style="list-style-type: none"> ▪ Intelligent Endoscopy Ecosystem¹

¹ For disclosure purposes, financial results of Intelligent Endoscopy Ecosystem are classified as Surgical Endoscopy.

Key Product Catalysts: Therapeutic Solutions Division (As of Nov. 8, 2024)



✔ TSD Key priorities for FY2025

GI EndoTherapy

- Expand clinically differentiated product offerings in key areas of focus: ERCP, ESD, Luminal Patency and Hemostasis devices

Urology

- Expand leadership in BPH through iTind market development while maintaining resection as a primary revenue and profit growth
- Drive lithotripsy growth through SOLTIVE SuperPulsed Laser System

Respiratory

- Drive growth in lung cancer with stronger emphasis around updated EBUS-TBNA offering.
- Reinforce strength in respiratory endoscopy through continued focus on driving adoption of X1 bronchoscopy platform

Expected Growth Rates
in FY2025

8%

YoY

4%

After FX
adjustment

Growth driver now

GI EndoTherapy

- Visiglide series
- ESD Knife
- EndoJaw

Urology

- Resection electrodes **with ESG-410**
- SOLTIVE SuperPulsed Laser System for stone + soft tissue (US, EU, AP)

Respiratory

- Single-use bronchoscope (US)
- Bronchoscope, EBUS scope
- ViziShot series
- Spiration Valve System
- EVIS X1 bronchoscope (Japan, EU, AP)

Just launched / Coming soon

GI EndoTherapy

- 3 product (US)
- 3 products (EU)
- 1 products (Japan)
- 2 product (China)

Urology

- Single-use ureteroscope (US, AP, Japan)
- SOLTIVE SuperPulsed Laser System (Japan)
- iTind (US, EU, AP)
- 4K Camera Head (US, EU, AP, Japan)**
- VISERA S (US, EU, AP, Japan)**
- Resection electrodes (China)
- OES ELITE Ureteroscope (China)

Respiratory

- New EBUS scope (US, China)
- EVIS X1 bronchoscope (US)
- Endoscopic Ultrasound Processor (EU, Japan, AP)

Beyond

GI EndoTherapy

- Single-use cholangioscope
- EUS Needle**
- New Hemostasis Clip**

Urology

- Cystoscope
- Laser system**

Respiratory

- Slim EBUS scope
- EVIS X1 bronchoscope (China)

Fiscal Year 2025 Quarterly Consolidated Financial Results

		3 Months (Jul. to Sep.)								
		FY2024 2Q	FY2025 2Q	YoY	FY2024 1Q	FY2024 2Q	1Q vs 2Q	FY2025 1Q	FY2025 2Q	1Q vs 2Q
Continuing operations ¹	(Billions of yen)									
	Revenue	226.6	239.2	+6%	205.0	226.6	+11%	234.8	239.2	+2%
	Gross profit	149.7	166.8	+11%	135.6	149.7	+10%	156.2	166.8	+7%
	(% of revenue)	(66.0%)	(69.7%)	(+3.7%)	(66.1%)	(66.0%)	(-0.1%)	(66.5%)	(69.7%)	(+3.2%)
	Selling, general and administrative expenses	111.4	119.1	+7%	107.1	111.4	+4%	118.8	119.1	0%
	(% of revenue)	(49.2%)	(49.8%)	(+0.6%)	(52.3%)	(49.2%)	(-3.0%)	(50.6%)	(49.8%)	(-0.7%)
	Other income and expenses	-57.1	-4.6	-	-5.8	-57.1	-	-9.9	-4.6	-
	Operating profit	-18.9	43.1	-	22.6	-18.9	-	27.5	43.1	+57%
	(% of revenue)	(-)	(18.0%)	(-)	(11.0%)	(-)	(-)	(11.7%)	(18.0%)	(+6.3%)
	Adjusted operating profit	38.2	47.8	+25%	28.3	38.2	+35%	37.2	47.8	+28%
(% of revenue)	(16.9%)	(20.0%)	(+3.1%)	(13.8%)	(16.9%)	(+3.1%)	(15.9%)	(20.0%)	(+4.1%)	
Profit before tax	-21.9	42.4	-	19.8	-21.9	-	26.4	42.4	+61%	
(% of revenue)	(-)	(17.7%)	(-)	(9.7%)	(-)	(-)	(11.2%)	(17.7%)	(+6.5%)	
Discontinued operation	Profit (loss)	-24.0	34.4	-	240.6	-24.0	-	14.6	34.4	+136%
Profit (loss) attributable to owners of parent	-24.3	34.4	-	240.6	-24.3	-	14.6	34.4	+136%	

¹ The figures from "Revenue" to "Profit from continuing operations" represent continuing operations.

2Q of Fiscal Year 2025 Other Income and Expenses

6 Months (Apr. to Sep.)

(Billions of yen)	FY2024	FY2025	Change
Other income	1.4	2.9	+1.5
Major items		<ul style="list-style-type: none"> Reversal of provision for lawsuits against Chinese manufacturing subsidiaries as a result of settlements 1.3 (Elimination and Corporate) 	
Other expenses	64.2	17.4	-46.7
Major items	<ul style="list-style-type: none"> Losses related to Veran Medical Technologies Inc. 49.6 (TSD) Expenses related to FDA remediation¹ 11.9 (ESD, TSD) 	<ul style="list-style-type: none"> Expenses related to holistic remediation and transformation program "Elevate" 11.0 (ESD, TSD) Expenses related to "Career support for external opportunity" program 2.8 (ESD, TSD, Elimination and Corporate) 	

¹ This item is currently referred to as the expenses related to holistic remediation and transformation program "Elevate".

* Amounts in this slide are related to continuing operations only.

Capital Allocation

Policy

- ☑ Prioritize allocation to business investment
- ☑ Stable and gradual dividend increase
- ☑ Flexible buyback of company shares

FY2025


- ☑ Active investment in three focus areas
- ☑ Plan to increase annual dividend by ¥2/share YoY to ¥20/share
- ☑ Share buyback of ¥100 billion is in progress (Total approx. ¥79.8 billion as end of Oct.)



Expenditures: 2Q of Fiscal 2025 Actuals and Full-year Forecasts

6 Months (Apr. to Sep.) and Forecasts¹

(Billions of yen) ■ FY2024 2Q ■ FY2025 2Q ■ FY2025 (Forecasts)



(Billions of yen)	FY2024	FY2025
R&D expenditures ² (a)	38.3	43.2
Capitalization of R&D expenditures (b)	6.0	6.9
R&D expenses in P/L (a-b)	32.3	36.3

(Billions of yen)	FY2024	FY2025
Amortization	4.2	3.9

	End of Jun. 2024	End of Sep. 2024
R&D assets	62.2	60.0

¹ Amounts in this slide are related to continuing operations only.

² Capitalization of R&D expenditures (b) is included in R&D expenditures.

³ Capitalization of R&D expenditures (b) is included in capital expenditures.

In addition, the Olympus Group has adopted IFRS #16 "Leases" from FY2020, and right-of use assets below are included in capital expenditures.

(FY2024 2Q: ¥6.9 billion, FY2025 2Q: ¥8.0 billion, FY2025 Forecast: ¥14.0 billion)

Foreign Exchange and Sensitivity

No change in FX rate assumptions for full-year forecasts

Foreign exchange rate

(Yen)	FY2024 1Q	FY2024 2Q	FY2025 1Q	FY2024 2Q	FY2025 Forecasts
Yen/U.S.dollar	137.37	144.62	155.88	149.38	151
Yen/Euro	149.47	157.30	167.88	164.01	163
Yen/CNY	19.56	19.94	21.48	20.82	21

Forex sensitivity (annualized impact)

(Billions of yen)	Revenue	Operating profit
U.S. dollar (per yen)	2.6	0.5
Euro (per yen)	1.6	0.5
CNY (per yen)	5.2	2.7

* Amounts in the above table are related to continuing operations only. Forex sensitivity (annualized impact) is calculated based on the FY2024 Q4 results.

Acronyms

Acronyms	Term
APAC	Asia Pacific
BPH	Benign Prostatic Hyperplasia
EBUS-TBNA	Endobronchial Ultrasound-guided Transbronchial Fine Needle Aspiration
ERCP	Endoscopic Retrograde Cholangio Pancreatography
ESD	Endoscopic Submucosal Dissection
HPB	Hepato-Pancreato-Biliary

Web Links for 2Q of Fiscal 2025 Consolidated Financial Results (Jul. - Sep.)

Please refer to “Financial Data for the 2nd Quarter of FY2025” for 2Q results (Jul.-Sep.) of Fiscal 2025.

Item	URL
Consolidated Financial Summary	https://www.olympus-global.com/ir/data/brief/pdf/02_data_Q2FY2025_en.pdf#page=2
Information by Business Segment- Medical Business・ESD・TSD	https://www.olympus-global.com/ir/data/brief/pdf/02_data_Q2FY2025_en.pdf#page=3
Information by Business Segment- Corporate Expenses	
Expenditures etc.	https://www.olympus-global.com/ir/data/brief/pdf/02_data_Q2FY2025_en.pdf#page=6
Consolidated Statement of Cash Flows	